Nektar Therapeutics, Senior Vice President of Biology and Preclinical Development Explores Enhanced Cancer Vaccine Effectiveness
Aimed at an audience of senior scientists and oncology specialists involved in targeted vaccines and drug research, Cancer Vaccines 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of cancer immunotherapy. The 6th annual show will capture expert insight by honing in on new pathways with novel vaccines and immunotherapies, drug formulations, personalised treatment, immune check-point inhibitors and much more.
London, United Kingdom, August 29, 2017 --(PR.com)-- SMi Group has announced that Johnathan Zalevsky, Senior Vice President Biology & Preclinical Development, Nektar Therapeutics will be chairing day two of the 6th annual Cancer Vaccines conference, which will be taking place on September 27th & 28th 2017.
Johnathan is an immunologist, responsible for the research portfolio at Nektar. Possessing extensive experience on the understanding of cellular and humoral immunity as it relates to vaccination technology and the purpose of bringing forward drugs that interact with vaccination technologies, to potentiate the effectiveness of those therapies. Mr Zalevsky joins a speaker lineup comprised of experts shaping the oncology landscape in Europe including representatives from Agenus, ImmuniTrack, BioNTech AG, Onyvax, MSD, Exicure and more.
Johnathan’s presentation will be focused on the ‘Enhanced Cancer Vaccine Effectiveness With NKTR-214 A CD 122-Biased Cytokine’. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting CD8+ effector T cells and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD1 on these immune cells may enable the next generation of tumour vaccines.
This year, the conference will also explore significant developmental topics within the sector including the impact of a generation of fully personalised cancer therapies with a potent, cost-effective and robust technology, how do we define 'successful' treatment, immune modulation and much more.
A detailed agenda and speaker line-up is available at www.cancervaccinesevent.com
Running alongside the conference will an exclusive pre-conference workshop held on Tuesday 26th September 2017.
Workshop: Biomakers of Immune Response
Workshop hosts:
Rose-Ann Padua, Research Director, INSERM
Antoine Toubert, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM
Eric Tartour, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou
Sharam Kordasti, Senior Lecturer, Kings College London
Zwi Berneman, Professor of Haematology, University of Antwerp
Cancer Vaccines 2017 is proudly sponsored by Northwest Biotherapeutics
For sponsorship packages: Contact Alia Malick +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk.
For delegate enquiries: Contact Sean Vaghela on +44 (0) 20 7827 6744 or email saghela@smi-online.co.uk
For media enquiries, contact Kyra Williams on +44 (0) 20 7827 6012 or email kwilliams@smi-online.co.uk
6th annual Cancer Vaccines
27th – 28th September 2017
London, UK
www.cancervaccinesevent.com
Contact e-mail: kwilliams@smi-online.co.uk
Contact tel: +44 (0) 207 827 6012
#smicancervac
Johnathan is an immunologist, responsible for the research portfolio at Nektar. Possessing extensive experience on the understanding of cellular and humoral immunity as it relates to vaccination technology and the purpose of bringing forward drugs that interact with vaccination technologies, to potentiate the effectiveness of those therapies. Mr Zalevsky joins a speaker lineup comprised of experts shaping the oncology landscape in Europe including representatives from Agenus, ImmuniTrack, BioNTech AG, Onyvax, MSD, Exicure and more.
Johnathan’s presentation will be focused on the ‘Enhanced Cancer Vaccine Effectiveness With NKTR-214 A CD 122-Biased Cytokine’. NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting CD8+ effector T cells and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD1 on these immune cells may enable the next generation of tumour vaccines.
This year, the conference will also explore significant developmental topics within the sector including the impact of a generation of fully personalised cancer therapies with a potent, cost-effective and robust technology, how do we define 'successful' treatment, immune modulation and much more.
A detailed agenda and speaker line-up is available at www.cancervaccinesevent.com
Running alongside the conference will an exclusive pre-conference workshop held on Tuesday 26th September 2017.
Workshop: Biomakers of Immune Response
Workshop hosts:
Rose-Ann Padua, Research Director, INSERM
Antoine Toubert, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM
Eric Tartour, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou
Sharam Kordasti, Senior Lecturer, Kings College London
Zwi Berneman, Professor of Haematology, University of Antwerp
Cancer Vaccines 2017 is proudly sponsored by Northwest Biotherapeutics
For sponsorship packages: Contact Alia Malick +44 (0) 207 827 6168 or e-mail amalick@smi-online.co.uk.
For delegate enquiries: Contact Sean Vaghela on +44 (0) 20 7827 6744 or email saghela@smi-online.co.uk
For media enquiries, contact Kyra Williams on +44 (0) 20 7827 6012 or email kwilliams@smi-online.co.uk
6th annual Cancer Vaccines
27th – 28th September 2017
London, UK
www.cancervaccinesevent.com
Contact e-mail: kwilliams@smi-online.co.uk
Contact tel: +44 (0) 207 827 6012
#smicancervac
Contact
SMi Group
Kyra Williams
+44 (0) 20 7827 6102
http://www.cancervaccinesevent.com/prcom
Kyra Williams
+44 (0) 20 7827 6102
http://www.cancervaccinesevent.com/prcom
Contact
Categories